<DOC>
	<DOCNO>NCT01063010</DOCNO>
	<brief_summary>The purpose study perform pilot study ass potential use Bevacizumab ( vascular endothelial growth factor ( VEGF ) inhibitor ) sepsis .</brief_summary>
	<brief_title>Pilot Study Bevacizumab ( Avastin ) Patients With Septic Shock</brief_title>
	<detailed_description>Sepsis responsible significant morbidity , mortality , cost patient healthcare system . The hospital case mortality rate severe sepsis ( sepsis acute organ system dysfunction ) 30-50 % ,7-12 incidence approximately 751,000 case 215,000 death nationally per year . The overall cost care estimate $ 16.7 billion annually US.Despite significant advance medical science , overall mortality rate severe sepsis improve substantially time . VEGF signal sepsis . VEGF contribute inflammation coagulation - key element sepsis pathophysiology . For example , vitro condition , VEGF induce expression cell adhesion molecule ( E-selectin , ICAM-1 , VCAM-1 ) endothelial cell promote adhesion leukocyte . Moreover , VEGF signal upregulates tissue factor mRNA , protein procoagulant activity . Several study show increase circulating level VEGF patient sepsis . In one study , maximum VEGF level increase survivor versus non-survivors sepsis . In another study patient meningococcal meningitis , elevate VEGF level associate shock upregulation IL-1beta , IL-10 , IL-12 , complement activation increase permeability.We additional human data 83 patient demonstrate association VEGF SOFA score , IL-1 , IL-6 . Consistent critical role inflammation , VEGF inhibition use VEGF trap result attenuation plasma interleukin IL-6 IL-10 level mouse cecal ligation puncture ( CLP ) model . VEGF signal important determinant sepsis morbidity mortality animal model . We recently show sepsis associate time-dependent increase circulating level VEGF animal human model sepsis.2 The overexpression sFlt-1 well addition exogenous sFLT-1 ( bind neutralizes VEGF ) mouse attenuate lipopolysaccharide- CLP-mediated mediate morbidity ( cardiac dysfunction , vascular permeability endothelial activation ) mortality sepsis . Importantly , finding reproduce extend others.6 The strike reproducible reduction morbidity mortality make compelling case exploration human sepsis . A role Bevacizumab treat patient severe sepsis . There several advantage employ Bevacizumab lead agent inhibit VEGF signal patient severe sepsis . First , humanize monoclonal antibody , sufficiently long half-life may give single injection patient population . Second , already FDA approve use patient certain type cancer . Thus , extensive knowledge pharmacokinetics pharmacodynamics ( least latter population ) . Moreover , difficult obtain permission use septic patient . Third , chief side effect , namely hypertension , major concern sepsis , since condition associate hypotension .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Septic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Eligible patient adult patient , age &gt; 18 , meet follow inclusion criterion : 1 . Evidence infection a. temperature &gt; 100.4F &lt; 97.0F nonenvironmental cause , pneumonia determine presence infiltrate chest xray , noncontaminated urinalysis &gt; 10 WBC urine dipstick positive leukocyte esterase , abdominal CT scan yield diagnosis intraabdominal etiology , skin/soft tissue infection clinical exam . 2 . Two SIRS criterion a. tachycardia ( HR &gt; 90 ) b. tachypnea ( RR &gt; 20 ) hypoxia ( oxygen saturation &lt; 90 % ) c. hyperthermia &gt; 100.4 F ( 38C ) hypothermia &lt; 96F ( 35.5C ) d. leukocytosis WBC &gt; 15,000 cells/mm3 band &gt; 10 % ] 3 . Septic shock a. persistent hypotension ( SBP &lt; 90mmHg ) initial 2030 cc/kg fluid challenge , need vasopressor least 1 hour order maintain systolic blood pressure &gt; 90 mmHG ; enrollment within 48 hour meet eligibility criterion . DiseaseSpecific Exclusions : Inability obtain write informed consent patient appropriate designee General Medical Exclusions Life expectancy le 12 week BevacizumabSpecific Exclusions : Inadequately control hypertension Prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix E ) History myocardial infarction unstable angina within 12 month prior Day 1 History stroke transient ischemic attack within 12 month prior Day 1 Known CNS malignancy , except treat brain metastasis Significant vascular disease ( e.g. , aortic aneurysm , require surgical repair recent peripheral arterial thrombosis ) within 6 month prior Day 1 History hemoptysis within 1 month prior Day 1 History chronic bleeding diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 Serious , nonhealing wound , active ulcer , untreated bone fracture Proteinuria screen Known hypersensitivity component bevacizumab Pregnancy lactation Any clotting abnormality history deep venous thrombosis pulmonary embolus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>sepsis</keyword>
	<keyword>septic shock</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
</DOC>